A Palo Alto startup will focus an $18 million VC investment on developing a drug to stop unexplained recurrent miscarriages. Nora Therapeutics is capitalizing on work started by cofounder Darryl Carter at Johns Hopkins University that led to development of Nora’s lead drug, NT-100. Nora is led by CEO Jeff Tong, who had been vice president of corporate and product development at Infinity Pharmaceuticals Inc. (NASDAQ:INFI). Infinity Pharmaceuticals Inc. (NASDAQ:INFI) stock performance was -5.05% in last session and finished the day at $9.97. Traded volume was 521,266.00million shares in the last session and the average volume of the stock remained 655.81K shares. The beta of the stock remained 0.82. Infinity Pharmaceuticals Inc. (NASDAQ:INFI) insider ownership is 0.20%.

Corcept Therapeutics Incorporated (NASDAQ:CORT) entered into a manufacturing agreement (the “Agreement”) with AAIPharma Services Corp. (“AAI”), pursuant to which AAI will manufacture and package Korlym tablets (the “product”). We will supply mifepristone, the active pharmaceutical ingredient in Korlym, to AAI for use in the manufacture of the product. AAI will manufacture the product in accordance with FDA and other regulatory requirements. Corcept Therapeutics Incorporated (NASDAQ:CORT) dropped -6.07 percent to 4.02 Wednesday on volume of 532,231.00million shares. The intra-day range of the stock was $3.99 to $4.27. Corcept Therapeutics Incorporated (NASDAQ:CORT) has a market capitalization of $404.77million.

Puma Biotechnology Inc (NYSE:PBYI) last issued its quarterly earnings data on Monday, March 3rd. The company reported ($0.46) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.49) by $0.03. On average, analysts predict that Puma Biotechnology Inc (NYSE:PBYI) will post $-2.09 earnings per share for the current fiscal year. Puma Biotechnology Inc (NYSE:PBYI)’s stock on Apr 23, 2014 reported a decrease of -7.10% to the closing price of $77.83. Its fifty two weeks range is $27.40 -$143.65. The total market capitalization recorded $2.34billion. The overall volume in the last trading session was 402,621.00million shares. In its share capital, PBYI has 30.12million outstanding shares.

Conatus Pharmaceuticals Inc (NASDAQ:CNAT) is developing its lead compound, emricasan, for the treatment of patients in orphan populations with chronic liver disease and acute exacerbations of chronic liver disease. On Wednesday, shares of Conatus Pharmaceuticals Inc (NASDAQ:CNAT) dropped -5.75% to close the day at $6.39. Company monthly performance is recorded as -29.08%. Conatus Pharmaceuticals Inc (NASDAQ:CNAT) quarterly revenue growth is -42.22%.